1. Technology Strategy Board Driving Innovation FP7 2012 Research Funding Overview Graham Hughes, FP7UK NCP for Health (Industry)

2. Technology Strategy Board Driving Innovation “FP7 work programmes will “continue to secure world excellence in basic research” through large scale collaborative research efforts JM Barroso 2009

3. Technology Strategy Board Driving Innovation FP7 - €53 billion spend 2007 - 2013

4. Technology Strategy Board Driving Innovation Cooperation Theme

5. Technology Strategy Board Driving Innovation Three Major Objectives Improve the health of European citizens Boost the competitiveness of health related industries Address global health issues Also seeking to implement research objectives that help to realise the aims of the Innovation Union (Europe 2020) flagship initiative. Health Theme Objectives

6. Technology Strategy Board Driving Innovation The Health Theme: Structure Activity 1: Biotechnology, generic tools & technologies for health Activity 2: Translating research for human health Activity 3: Optimising the delivery of health care cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues Activity 4: Support actions & response to policy needs The Innovative Medicines Initiative

7. Technology Strategy Board Driving Innovation Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded 2007€641 million153 2008€577 million172 2009€611 million105 2010€621 million131 2011€650 million~126 2012€620 million? 2013€780 million?

8. Technology Strategy Board Driving Innovation UK Performance Health Funding totals 2007 -2009 – All Participations

9. Technology Strategy Board Driving Innovation UK FP7 Health Theme in Numbers* UK based submissions 3264* UK based participations 859 93 projects have UK based Coordinators Participations by organisation activity type (relative shares) Secondary & Higher Education Private Commercial Research OrganisationPublic BodyOther UK74.411.512.01.0 Germany54.319.722.12.71.2 France15.421.156.42.54.7 All Countries50.214.927.45.12.4 *2007 – 2009 data – from GAs and participants database (released on 1 May 2010 - data cut-off date 25 March 2010

10. Technology Strategy Board Driving Innovation SME Participation 52 UK SMEs in active FP7 projects (plus 17 new 2010)

11. Technology Strategy Board Driving Innovation Collaborative Research:Why? Access significant research funding 75% RTD costs and 100% management and training costs EU contribution between €2 and 12 million Strengthening Research Capabilities Increased collaboration between basic and clinical researchers, regulatory bodies and patient groups Access to new networks and contacts develop new business contacts from the linkages formed in a consortium Access to IP and facilities otherwise unavailable Elevated Profile Publications, CORDIS

12. Technology Strategy Board Driving Innovation Collaborative Research: Who? Countries EU Member States – broadest rights and access Associated Countries – e.g. Iceland, Norway, Turkey, Israel International Cooperation Partner Countries (ICPC) – e.g. Russia, Central Asian, Balkan, North African countries Industrialised high-income countries (e.g Australia, Korea, Japan) – self financing. USA has reciprocal arrangement Co-operation with “third countries” explicitly encouraged in FP7 Organisations research groups at universities or research institutes innovative companies (SMEs and larger) public or governmental administration (eg NHS trusts) Charities and other not for profit organisations

13. Technology Strategy Board Driving Innovation Collaborative Research: How? Get hold of call topics – earlier the better –Speak to your NCP Read the topics carefully – check with NCP –Correct fit is crucial Pull together consortium/search for consortium to join –Use own networks if possible –Utilise all resources Develop project ideas and plan –Make sure it meets the objectives of the call Wait for call documents on Cordis website (July) Develop proposal – outline only for 2 Stage Submit by deadline (October)

14. Technology Strategy Board Driving Innovation WP First Draft Open day (Brussels) 09 June 2011 Call published Stage 1 Deadline NCP Roadshow Evaluation results Evaluation PC Meetings Collaborative Research: When?

15. Technology Strategy Board Driving Innovation Support and Further Information

16. Technology Strategy Board Driving Innovation Informing and Awareness Raising –Call documents and supporting information –Website and printed newsletters, e-bulletins –Promotional activities – info days, seminars, –Signposting – other themes + funding schemes Advising and Training –Helpline – e-mail and telephone enquiries –Partner search –Direct support Feedback and Signposting –Problems or difficulties during implementation or participation –Direct contact with EU Scientific Officers –Identifying and communicating other areas of support and funding NCP Support All advice is impartial, confidential and free

17. Technology Strategy Board Driving Innovation Support and Further Information Website https://ktn.innovateuk.org/web/fp7ukhttps://ktn.innovateuk.org/web/fp7uk E mail graham.hughes@betatechnology.co.ukgraham.hughes@betatechnology.co.uk Phone 01302 322633 Mobile 07775 584028 Alternative victoria.brewer@headoffice.mrc.co.uk +44 (0)20 7395 2205

18. Technology Strategy Board Driving Innovation 2012 Call – Context Innovation Union research and innovation are key drivers of competitiveness, jobs, sustainable growth and social progress. More topics targeting knowledge generation to deliver innovative products, processes and services. The “Expected Impact” section of topic descriptions will reflect this. Challenge led programme More emphasis on exploitation issues such as dissemination, IP protection and knowledge generation.

19. Technology Strategy Board Driving Innovation 2012 Call – Shift in Focus Challenge driven – fewer areas open, multiple projects in each area. (33 topics total) –Aim to mobilise critical mass of resources and implement coherent set of actions Stronger socio-economic impact –More emphasis on knowledge transfer and IPR management Balance upstream research and activities closer to market to achieve short and medium-term outcomes –E.g. focus on medical technologies Flexibility for consortium, duration and budget

20. Technology Strategy Board Driving Innovation 2012 Call – Closed Areas 1.1 High Throughput Research 1.3 Suitability, Safety and Efficacy of Therapies* 2.2.1 Brain and Brain Related Diseases 2.3.1 Anti Microbial Drug Resistance 2.3.3 Potentially New and Re-emerging Epidemics 2.3.4 Neglected Infectious Diseases* 2.4.1 Cancer 2.4.2 Cardiovascular Disease 3.1 Translating the Results of Clinical Research Outcome 3.3 Health Promotion and Prevention 4.2 Responding to EU Policy Needs

21. Technology Strategy Board Driving Innovation 2012 Call Overview SME Focus Active and Healthy Ageing Medical Technologies Rare Diseases Clinical Trials Personalised and Regenerative Medicine Systems Biology HIV/AIDS, Malaria and TB Healthcare delivery Coordination and Support Activities

22. Technology Strategy Board Driving Innovation 2012 Call – SME Focused Two stage submission/evaluation Several funded proposals per topic Small – medium sized projects –€3m or €6m EC contribution –2 – 5 year duration SME targeted topics –10 Minimum 30% of EC contribution to SMEs –6 Minimum 15% of EC contribution to SMEs –20- 50% of EC funding to SMEs (€125 million) “SME friendly” topics (Technology/Methods based) Open topic descriptions (bottom up) > 30% >15%

23. Technology Strategy Board Driving Innovation Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded SME Targeted 2 Stage 2007€641 million1530%0 2008€577 million1720%0 2009€611 million1050%0 2010€621 million1310%19% 2011€650 million~12620%75% 2012€620 million?53%100% 2013€780 million?~ 50%100%

24. Technology Strategy Board Driving Innovation 2012 Call – Research Priorities #1 Ageing Must meet Europe 2020 objectives of active and healthy ageing: –Healthy, active and independent lives until old age –Ensure the sustainability and efficiency of social and healthcare systems –Create a European/Global market for innovative products andservices related to healthy and active ageing Align with Joint Programming Initiative on Neurodegenerative Diseases (JPND) –Addresses basic science, clinical research and healthcare research –23 participating countries –2011: Pilot call (€6-8 million) focussing on standardisation of biomarkers in NG diseases www.neurodegenerationresearch.eu

25. Technology Strategy Board Driving Innovation 2012 Call – Ageing Topics 2.2.2-1 Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related conditions 6,000,000>1 2.2.2-2 Investigator-driven clinical trials for optimisation of treatment for elderly patients with multiple diseases 6,000,000>1 Related topics Core topics 2.1.1-2 Validation of -omics based biomarkers for diseases affecting the elderly 12,000,000>1 2.4.5-1Technological approaches to to combating sensory impairments6,000,000>1 2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system 6,000,000>1 > 30% >15% > 30% >15%

26. Technology Strategy Board Driving Innovation 2012 Call – Research Priorities #2 Medical Technologies 1.4-1Innovative approaches to solid organ transplantation6,000,000>1 1.4-2 Medical technology for the transplantation sector and bio-artificial organs 6,000,000>1 2.3.0-1Diagnostics for infectious diseases6,000,000>1 2.4.3-1Innovative approach to manage diabetes6,000,000>1 2.4.5-1Technological approaches to combating sensory impairments6,000,000>1 2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system 6,000,000>1 3.2-2New methodologies for health technology assessment3,000,000>1 >15% > 30% >15% Supporting the “innovation” strategy and closer to market approach

27. Technology Strategy Board Driving Innovation 2012 Call – Research Priorities #3 Rare Diseases Build a critical mass for research into rare diseases High Impact Project: €30 million EC contribution 2.1.1-1 Clinical utility of -omics for better diagnosis and treatment of rare diseases 30,000,000 2.4.4-1 Preclinical and/or clinical development of substances with a clear potential as orphan drugs 6,000,000>1 2.4.4-2Observational trials in rare diseases3,000,000>1 2.4.4-3 Best practice and knowledge sharing in the clinical management of rare diseases 2,000,0001 4.1-4Support for international rare disease research1,000,0001 Support Action > 30%

28. Technology Strategy Board Driving Innovation 2012 Call – Research Priorities #4 Clinical Trials Continue the initiative started in the 2011 call Improve quality of clinical trials data in Europe Funding for Stage II,III or IV clinical trials as RTD activities (i.e. 75% EC contribution) 2.2.2-2 Investigator-driven clinical trials for optimisation of treatment for elderly patients with multiple diseases 6,000,000>1 2.4.3-2Investigator-driven clinical trials for type 1 diabetes research6,000,000>1 2.4.4-1 Preclinical and/or clinical development of substances with a clear potential as orphan drugs 6,000,000>1 2.4.4-2Observational trials in rare diseases3,000,000>1 > 30% >15%

29. Technology Strategy Board Driving Innovation 2012 Call – Personalised Medicine and Regenerative Medicine 1.2.1 Development of technologies with a view to patient group stratification for personalised medicine applications 6,000,000>1 1.4-1Innovative approaches to solid organ transplantation6,000,000>1 1.4-3 Innovative strategies for translation of stem cell based therapies in regenerative medicine 3,000,0001 1.4-4 Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach 6,000,000>1 Miscellany of topics mopping up areas covered in previous calls + new >15% > 30%

30. Technology Strategy Board Driving Innovation 2012 Call – Systems Biology Topics medical needs should drive systems biology research using systems medicine to improve understanding of disease mechanisms, prognosis and diagnosis of common diseases Coordinate European research activities for systems biology applications to medicine 2.1.2-1 Systems medicine: Applying systems biology approaches to address clinical needs 3,000,000>1 2.1.2-2 Systems medicine: Applying systems biology approaches for understanding common human diseases and their co-morbidities 12,000,000>1 2.1.2-3 Preparing for the future research and innovation activities in systems medicine 3,000,0001 > 30%

31. Technology Strategy Board Driving Innovation 2012 Call – HIV/AIDS Malaria and TB Co-infection and co-morbidity of HIV and other common infectious diseases poorly understood Prevention topic is looking for small, rapid projects o 1 – 3 years, €1 – 6 million funding Low cost interventions looking for solutions that can be implemented within the project period 2.3.2-1 Co-infection and co-morbidity in HIV/AIDS, malaria, tuberculosis and/or hepatitis 6,000,000>1 2.3.2-2Co-morbidity between infectious and non-communicable diseases6,000,000>1 2.3.2-3Prevention and treatment for HIV/AIDS, malaria and tuberculosis6,000,000>1 2.3.2-4Low-cost interventions for disease control in resource poor settings3,000,000>1 >15%

32. Technology Strategy Board Driving Innovation 2012 Call – Healthcare Delivery Addressing the need for systematic mapping of variations in health care practice and standardisation of health technology assessment Various areas of healthcare covered EU has strong political stance on healthcare equality 3.2-1Improving the organisation of health service delivery3,000,000>1 3.2-2New methodologies for health technology assessment3,000,000>1 3.4-1Health systems/services research in low and middle income countries6,000,000>1

33. Technology Strategy Board Driving Innovation 2012 Call – Coordination and Support Actions Various actions to complement research activities, develop infrastructure and determine future activities Strengthening exploitation of research is key focus Stronger socio-economic impact in EU funded research 4.1-1 Network to encourage technology transfer in FP-funded health research (especially in academic and governmental organisations) 2,000,0001 4.1-2 Training actions linked to intellectual property rights management and technology transfer 2,000,0001 4.1-3 Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union 100,000>1 4.1-5 Communicating the benefits of European research to the general public 1,000,0001

34. Technology Strategy Board Driving Innovation 2012 Call – ERA Net on Infectious Diseases Improve the linking, integration and coordination of national/regional programs for infectious disease research Develop new technologies and employ modern genomic approaches to advance understanding of pathogenic organisms and interactions with their hosts Foster development of infectious disease programs beyond MS and AC. Include a considerable number of MS that joined after 2003. EU Contribution €2,000,000  Impact: deepen and extend coordination of European research in infectious diseases

35. Technology Strategy Board Driving Innovation 09 June 2011: Open Info Day, Brussels 10 June 2011: Brokerage Event, Brussels July 2011: Call Opens – EPSS available Oct 2011: likely Stage 1 deadline Dec 2011: Stage 1 notification Feb 2012: Stage 2 deadline Key Dates

36. Technology Strategy Board Driving Innovation Other Health Related EU Funding Sources 2011 Nanosciences, Materials and Production NMP NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis NMP.2012.2.2-1: Biomaterials for improved performance of medical implants Likely timeframe similar to Health call

37. Technology Strategy Board Driving Innovation Other Health Related EU Funding Sources 2011 ICT 2011.5.2 Virtual Physiological Human a)Patient-specific predictive computer-based models and simulation of major diseases integrating medical, biological and environmental data b)Development of ICT tools, services and infrastructure to obtain more elaborate and reusable multi-scale models (e.g. models of diseases, organs) and larger repositories to show benefits of having both the data and models readily available c)Early demonstrators and proof of concept of digital representations of health status of patients integrating different patient-specific data and models of organs into a more coherent representation of a "Digital Patient". Budget = €66.5 Million Deadline 17 April 2011

38. Technology Strategy Board Driving Innovation Framework Programme 7 Hints and Tips For Proposal Writing Graham Hughes, FP7UK NCP for Health (Industry)

39. Technology Strategy Board Driving Innovation Initial Considerations Are you ready for participation? –Does it fit your aspirations/business plan –Collaborative projects mean working alongside international partners. Does this suit you way of working? Can you pull together or find a consortium? –Funding is highly competitive, prepare to be disappointed –Do you want to lead a project? (Time/resource) –Is the level of funding appropriate? –Can you wait 1 year for the money?

40. Technology Strategy Board Driving Innovation Read All Relevant Call Documentation http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction=UserSite.CooperationDetailsCallPa ge&call_id=323#infopack Call Fiche Work Programme Annexes Guide for Applicants

41. Technology Strategy Board Driving Innovation Understanding the Topic

42. Technology Strategy Board Driving Innovation Eligibility Criteria Look out for other criteria in the call text

43. Technology Strategy Board Driving Innovation Three Evaluation Criteria Proposals are evaluated against three criteria Must meet the threshold (and more) for all three

44. Technology Strategy Board Driving Innovation Scientific and Technical Quality “ Scientific and/or technological excellence ( relevant to the topic addressed by the call) ” Evaluated against: Soundness of concept and quality of objectives Progress beyond state of the art Quality and effectiveness of the S/T methodology and associated work plan

45. Technology Strategy Board Driving Innovation Implementation “ Quality and efficiency of the implementation and the management ” Evaluated Against: Appropriateness of the management structure and procedures Quality and relevant experience of individual participants Quality of the consortium as a whole (complementarity, balance) Appropriateness of the allocation and justification of the resources to be committed (budget, staff, equipment)

46. Technology Strategy Board Driving Innovation Impact “Potential impact through the development, dissemination and use of project results” Evaluated against: Contribution, at the European and/or international level, to the expected impacts listed in the work programme Appropriateness of measures for the dissemination and/or exploitation of project results, and management of IP

47. Technology Strategy Board Driving Innovation Ethics Ethics review is a legal requirement for FP7 projects Reviewed by independent Ethics review team Considers design and methodology for: –Intervention on humans –Use of animals –Data protection –Participation of children and other vulnerable groups Recommendations may be stipulated in the GA

48. Technology Strategy Board Driving Innovation Submission PIC will populate form with financial and other info. Can search for PIC number by organisation Check that you have registered for correct call ! Save early and save often Submit drafts well before the deadline NCP cannot help with EPSS problems !

49. Technology Strategy Board Driving Innovation Summary Competition is fierce – must be well over the threshold to succeed Remember the European aspect Read the call carefully – seek 2 nd and 3 rd opinions on topic fit Write simply and clearly – don’t assume expert knowledge Make time to do a good job – avoid last minute submissions Seek help early on

50. Technology Strategy Board Driving Innovation Lobbying for Future Topics

51. Technology Strategy Board Driving Innovation Life Cycle of the Work Programme ProjectsWork Programme Preparation PublicationDeadlines Grant Agreement NegotiationEvaluation Application InputsDrafts Comments Road map Sept 2010 Late Jan 2011 Late July 2011 Early Feb 2011 Mid Oct / Early Nov 2011 (est’.)

52. Technology Strategy Board Driving Innovation Life Cycle of the Work Programme ProjectsWork Programme Preparation PublicationDeadlines Grant Agreement NegotiationEvaluation Application InputsDrafts Comments Road map Sept 2010 Late Jan 2011 Late July 2011 Early Feb 2011 Mid Oct / Early Nov 2011 (est’.)

53. Technology Strategy Board Driving Innovation Who feeds into the work programme? –EU Com strategy –Advisory Group –PC delegations – all 27 Member States –Stakeholder / lobby groups e.g. researchers / project holders e.g. societies e.g. European Technology Platforms (ETPs) –Others...

54. Technology Strategy Board Driving Innovation UK Position UK position HEIs UK Lobbying ROs SMEs

55. Technology Strategy Board Driving Innovation Topic submission and amendments: Consider the UK’s: Research strategy (national and organisational) Strong active areas of research – critical mass How does this fit with FP7 and what the EC are looking for Broad topics – balance the need of the one against the many –Understand what the EC is looking for i.e. scientific road map –Know what has previously been funded – EC unlikely to fund similar topics/projects in consecutive years –Make reasonable suggestions: Justify why you want the changes/amendments Look towards scientific areas and not specific projects In addition, you can: Engage with the Scientific and Project Officers –Face to face meetings –Invite to workshops etc Ask you partners to lobby their NCPs and PMC members